Format

Send to

Choose Destination
Transfus Med Rev. 2014 Jan;28(1):23-8. doi: 10.1016/j.tmrv.2013.12.001. Epub 2013 Dec 16.

Anti-KANNO: a novel alloantibody against a red cell antigen of high frequency.

Author information

1
Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University Hospital, Fukushima, Japan. Electronic address: kawabata@fmu.ac.jp.
2
Blood Group Section, Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.
3
Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University Hospital, Fukushima, Japan.
4
Department of Laboratory Testing, Japanese Red Cross Yamagata Blood Center, Yamagata, Japan.
5
Department of Laboratory Testing, Japanese Red Cross Tohoku Block Blood Center, Miyagi, Japan.

Abstract

We encountered a broadly reactive red cell alloantibody in 1991, reacting unlike any other known antibody, and named it anti-KANNO after the first patient. A total of 28 cases of anti-KANNO in the Japanese literature were reviewed. To distinguish KANNO from other antibodies against high-frequency antigens, including anti-JMH, anti-Ch/Rg, and anti-Jr(a), we conducted serologic studies with proteolytic enzyme and chemical treatments, complement sensitization against red cells, and serum neutralization techniques. Reactivity of anti-KANNO against red cells lacking high-frequency antigens and antisera to high-frequency antigens against KANNO cells were tested. Among the 28 patients, 26 were female, of whom 25 had a history of pregnancy. Red cells from patient KANNO were reactive with antisera against antigens of high frequency. Anti-KANNO reacted weakly with all cells known to lack high-frequency antigens. It reacted with 2-aminoethylisothiouronium bromide, so it can be distinguished from anti-JMH. Differences among anti-KANNO, anti-Ch/Rg, and anti-Jr(a) emerged with enzyme-treated cells, complement-sensitized cells, and the addition of normal serum. As yet, there are no reports of hemolytic transfusion reaction or hemolytic disease of the fetus and newborn attributable to anti-KANNO. It appears that anti-KANNO is a newly characterized antibody more likely stimulated by pregnancy than by transfusion and with little or no clinical significance. Further surveillance and investigation of anti-KANNO, its antigen biochemistry, and its genetics are warranted.

PMID:
24485899
DOI:
10.1016/j.tmrv.2013.12.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center